Barak Zafrir1, Shai Cohen. 1. Department of Internal Medicine B, Lady Davis Carmel Medical Center, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 7 Michal St., Haifa 34362, Israel.
Abstract
BACKGROUND: Recent updated guidelines expand the usage of lipid-lowering therapy for primary prevention in high-risk individuals without an established cardiovascular disease (CVD). In contrast to secondary prevention, the extent of the target population and the utilization of lipid-lowering drugs are insufficiently clear. We examine the implementation of statin therapy as primary prevention in high-risk patients without a known CVD and discuss the rationale for the management of dyslipidemia in this population. METHODS: Records of 371 consecutive patients without an established CVD who were hospitalized in an internal medicine department between January and June 2005 were evaluated for CVD-equivalent high-risk factors (diabetes mellitus, stroke of carotid origin, peripheral vascular disease, abdominal aortic aneurysm, or Framingham 10-year risk score >/=20%). Demographic and clinical data, in addition to lipid profile and usage of statin drugs prior to and during hospitalization, were analyzed. RESULTS: Of the 371 non-cardiovascular patients, 88 (24%) were defined as high-risk individuals eligible for statin therapy as primary prevention of CVD. Their mean age was 71+/-11 years and their mean LDL-C level was 132+/-30 mg/dL. Seventeen patients (19%) were treated with statin drugs prior to admission and only two more patients (19/88, 22%) received statins in addition during hospitalization. Patients treated with statins had non-significantly higher LDL-C levels. CONCLUSIONS: There is considerable undertreatment of high-risk patients without an established CVD with lipid-lowering drugs. There is also sub-optimal implementation of guidelines in clinical practice, despite well-established evidence of the benefits of statins in the primary prevention of CVD for high-risk individuals with average cholesterol levels, diabetes mellitus, and in elderly patients, as represented by our study population.
BACKGROUND: Recent updated guidelines expand the usage of lipid-lowering therapy for primary prevention in high-risk individuals without an established cardiovascular disease (CVD). In contrast to secondary prevention, the extent of the target population and the utilization of lipid-lowering drugs are insufficiently clear. We examine the implementation of statin therapy as primary prevention in high-risk patients without a known CVD and discuss the rationale for the management of dyslipidemia in this population. METHODS: Records of 371 consecutive patients without an established CVD who were hospitalized in an internal medicine department between January and June 2005 were evaluated for CVD-equivalent high-risk factors (diabetes mellitus, stroke of carotid origin, peripheral vascular disease, abdominal aortic aneurysm, or Framingham 10-year risk score >/=20%). Demographic and clinical data, in addition to lipid profile and usage of statin drugs prior to and during hospitalization, were analyzed. RESULTS: Of the 371 non-cardiovascular patients, 88 (24%) were defined as high-risk individuals eligible for statin therapy as primary prevention of CVD. Their mean age was 71+/-11 years and their mean LDL-C level was 132+/-30 mg/dL. Seventeen patients (19%) were treated with statin drugs prior to admission and only two more patients (19/88, 22%) received statins in addition during hospitalization. Patients treated with statins had non-significantly higher LDL-C levels. CONCLUSIONS: There is considerable undertreatment of high-risk patients without an established CVD with lipid-lowering drugs. There is also sub-optimal implementation of guidelines in clinical practice, despite well-established evidence of the benefits of statins in the primary prevention of CVD for high-risk individuals with average cholesterol levels, diabetes mellitus, and in elderly patients, as represented by our study population.
Authors: Anne K Monroe; Wei Fu; Michelle N Zikusoka; Lisa P Jacobson; Mallory D Witt; Frank J Palella; Lawrence A Kingsley; Wendy S Post; Todd T Brown Journal: AIDS Res Hum Retroviruses Date: 2015-03-09 Impact factor: 2.205
Authors: Ole Ahlehoff; Lone Skov; Gunnar Gislason; Jesper Lindhardsen; Søren Lund Kristensen; Lars Iversen; Stine Lasthein; Robert Gniadecki; Tomas Norman Dam; Christian Torp-Pedersen; Peter Riis Hansen Journal: PLoS One Date: 2012-04-30 Impact factor: 3.240
Authors: Kenny Mendoza-Herrera; Andrea Pedroza-Tobías; César Hernández-Alcaraz; Leticia Ávila-Burgos; Carlos A Aguilar-Salinas; Simón Barquera Journal: Int J Environ Res Public Health Date: 2019-10-22 Impact factor: 3.390